We performed double autologous PBSCT in one fulminantly relapsed ATL patient. Cryopreserved PBSCs containing tumour cells were thawed, and CD34+ cells were selected for by immunomagnetic beads, with the aim of decreasing the number of re-infused tumour cells. The patient received 0.72x10(6) and 0.90x10(6) CD34+ cells/kg. The graft contained less than 0.1% T cells. The patient had a very good recovery, and maintained a good quality of life, until she died on Day 339 after her first PBSCT in third relapse. We conclude that autologous PBSCT for ATL patient has benefit in some instances, and cryopreserved PBSCs can be used for CD34+ selection.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: